Skip to main content
Top
Published in: Drug Safety 9/2014

01-09-2014 | Review Article

Drug-Induced Hyperkalemia

Authors: Chaker Ben Salem, Atef Badreddine, Neila Fathallah, Raoudha Slim, Houssem Hmouda

Published in: Drug Safety | Issue 9/2014

Login to get access

Abstract

Hyperkalemia is a common clinical condition that can be defined as a serum potassium concentration exceeding 5.0 mmol/L. Drug-induced hyperkalemia is the most important cause of increased potassium levels in everyday clinical practice. Drug-induced hyperkalemia may be asymptomatic. However, it may be dramatic and life threatening, posing diagnostic and management problems. A wide range of drugs can cause hyperkalemia by a variety of mechanisms. Drugs can interfere with potassium homoeostasis either by promoting transcellular potassium shift or by impairing renal potassium excretion. Drugs may also increase potassium supply. The reduction in renal potassium excretion due to inhibition of the renin-angiotensin-aldosterone system represents the most important mechanism by which drugs are known to cause hyperkalemia. Medications that alter transmembrane potassium movement include amino acids, beta-blockers, calcium channel blockers, suxamethonium, and mannitol. Drugs that impair renal potassium excretion are mainly represented by angiotensin-converting enzyme inhibitors, angiotensin-II receptor blockers, direct renin inhibitors, nonsteroidal anti-inflammatory drugs, calcineurin inhibitors, heparin and derivatives, aldosterone antagonists, potassium-sparing diuretics, trimethoprim, and pentamidine. Potassium-containing agents represent another group of medications causing hyperkalemia. Increased awareness of drugs that can induce hyperkalemia, and monitoring and prevention are key elements for reducing the number of hospital admissions, morbidity, and mortality related to drug-induced hyperkalemia.
Literature
1.
go back to reference Sood MM, Sood AR, Richardson R. Emergency management and commonly encountered outpatient scenarios in patients with hyperkalemia. Mayo Clin Proc. 2007;82(12):1553–61.CrossRefPubMed Sood MM, Sood AR, Richardson R. Emergency management and commonly encountered outpatient scenarios in patients with hyperkalemia. Mayo Clin Proc. 2007;82(12):1553–61.CrossRefPubMed
3.
go back to reference Perazella MA. Drug-induced hyperkalemia: old culprits and new offenders. Am J Med. 2000;109(4):307–14.CrossRefPubMed Perazella MA. Drug-induced hyperkalemia: old culprits and new offenders. Am J Med. 2000;109(4):307–14.CrossRefPubMed
4.
go back to reference Miltiadous G, Mikhailidis DP, Elisaf M. Acid-base and electrolyte abnormalities observed in patients receiving cardiovascular drugs. J Cardiovasc Pharmacol Ther. 2003;8(4):267–76.CrossRefPubMed Miltiadous G, Mikhailidis DP, Elisaf M. Acid-base and electrolyte abnormalities observed in patients receiving cardiovascular drugs. J Cardiovasc Pharmacol Ther. 2003;8(4):267–76.CrossRefPubMed
5.
go back to reference Passare G, Viitanen M, Torring O, Winblad B, Fastbom J. Sodium and potassium disturbances in the elderly: prevalence and association with drug use. Clin Drug Investig. 2004;24(9):535–44.CrossRefPubMed Passare G, Viitanen M, Torring O, Winblad B, Fastbom J. Sodium and potassium disturbances in the elderly: prevalence and association with drug use. Clin Drug Investig. 2004;24(9):535–44.CrossRefPubMed
6.
go back to reference Noize P, Bagheri H, Durrieu G, Haramburu F, Moore N, Giraud P, et al. Life-threatening drug-associated hyperkalemia: a retrospective study from laboratory signals. Pharmacoepidemiol Drug Saf. 2011;20(7):747–53.CrossRefPubMed Noize P, Bagheri H, Durrieu G, Haramburu F, Moore N, Giraud P, et al. Life-threatening drug-associated hyperkalemia: a retrospective study from laboratory signals. Pharmacoepidemiol Drug Saf. 2011;20(7):747–53.CrossRefPubMed
7.
go back to reference Banerjee A, Stoica C, Walia A. Acute hyperkalemia as a complication of intravenous therapy with epsilon-aminocaproic acid. J Clin Anesth. 2011;23(7):565–8.CrossRefPubMed Banerjee A, Stoica C, Walia A. Acute hyperkalemia as a complication of intravenous therapy with epsilon-aminocaproic acid. J Clin Anesth. 2011;23(7):565–8.CrossRefPubMed
8.
go back to reference Barone R, Pauwels S, De Camps J, Krenning EP, Kvols LK, Smith MC, et al. Metabolic effects of amino acid solutions infused for renal protection during therapy with radiolabelled somatostatin analogues. Nephrol Dial Transplant. 2004;19(9):2275–81.CrossRefPubMed Barone R, Pauwels S, De Camps J, Krenning EP, Kvols LK, Smith MC, et al. Metabolic effects of amino acid solutions infused for renal protection during therapy with radiolabelled somatostatin analogues. Nephrol Dial Transplant. 2004;19(9):2275–81.CrossRefPubMed
9.
go back to reference Giovacchini G, Nicolas G, Freidank H, Mindt TL, Forrer F. Effect of amino acid infusion on potassium serum levels in neuroendocrine tumour patients treated with targeted radiopeptide therapy. Eur J Nucl Med Mol Imaging. 2011;38(9):1675–82.CrossRefPubMed Giovacchini G, Nicolas G, Freidank H, Mindt TL, Forrer F. Effect of amino acid infusion on potassium serum levels in neuroendocrine tumour patients treated with targeted radiopeptide therapy. Eur J Nucl Med Mol Imaging. 2011;38(9):1675–82.CrossRefPubMed
10.
go back to reference Hertz P, Richardson JA. Arginine-induced hyperkalemia in renal failure patients. Arch Intern Med. 1972;130(5):778–80.CrossRefPubMed Hertz P, Richardson JA. Arginine-induced hyperkalemia in renal failure patients. Arch Intern Med. 1972;130(5):778–80.CrossRefPubMed
11.
12.
go back to reference Carroll HJ, Tice DA. The effects of epsilon amino-caproic acid upon potassium metabolism in the dog. Metabolism. 1966;15(5):449–57.CrossRefPubMed Carroll HJ, Tice DA. The effects of epsilon amino-caproic acid upon potassium metabolism in the dog. Metabolism. 1966;15(5):449–57.CrossRefPubMed
13.
go back to reference Nzerue CM, Falana B. Refractory hyperkalaemia associated with use of epsilon-aminocaproic acid during coronary bypass in a dialysis patient. Nephrol Dial Transplant. 2002;17(6):1150–1.CrossRefPubMed Nzerue CM, Falana B. Refractory hyperkalaemia associated with use of epsilon-aminocaproic acid during coronary bypass in a dialysis patient. Nephrol Dial Transplant. 2002;17(6):1150–1.CrossRefPubMed
14.
go back to reference Lundborg P. The effect of adrenergic blockade on potassium concentrations in different conditions. Acta Med Scand Suppl. 1983;672:121–6.PubMed Lundborg P. The effect of adrenergic blockade on potassium concentrations in different conditions. Acta Med Scand Suppl. 1983;672:121–6.PubMed
15.
go back to reference Sica DA. Antihypertensive therapy and its effects on potassium homeostasis. J Clin Hypertens (Greenwich). 2006;8(1):67–73.CrossRef Sica DA. Antihypertensive therapy and its effects on potassium homeostasis. J Clin Hypertens (Greenwich). 2006;8(1):67–73.CrossRef
16.
go back to reference Bethune DW, McKay R. Paradoxical changes in serum-potassium during cardiopulmonary bypass in association with non-cardioselective beta blockade. Lancet. 1978;2(8085):380.CrossRefPubMed Bethune DW, McKay R. Paradoxical changes in serum-potassium during cardiopulmonary bypass in association with non-cardioselective beta blockade. Lancet. 1978;2(8085):380.CrossRefPubMed
17.
go back to reference Swenson ER. Severe hyperkalemia as a complication of timolol, a topically applied beta-adrenergic antagonist. Arch Intern Med. 1986;146(6):1220–1.CrossRefPubMed Swenson ER. Severe hyperkalemia as a complication of timolol, a topically applied beta-adrenergic antagonist. Arch Intern Med. 1986;146(6):1220–1.CrossRefPubMed
18.
go back to reference McCauley J, Murray J, Jordan M, Scantlebury V, Vivas C, Shapiro R. Labetalol-induced hyperkalemia in renal transplant recipients. Am J Nephrol. 2002;22(4):347–51.CrossRefPubMed McCauley J, Murray J, Jordan M, Scantlebury V, Vivas C, Shapiro R. Labetalol-induced hyperkalemia in renal transplant recipients. Am J Nephrol. 2002;22(4):347–51.CrossRefPubMed
19.
go back to reference Castellino P, Simonson DC, DeFronzo RA. Adrenergic modulation of potassium metabolism during exercise in normal and diabetic humans. Am J Physiol. 1987;252(1 Pt 1):E68–76.PubMed Castellino P, Simonson DC, DeFronzo RA. Adrenergic modulation of potassium metabolism during exercise in normal and diabetic humans. Am J Physiol. 1987;252(1 Pt 1):E68–76.PubMed
20.
go back to reference Arthur S, Greenberg A. Hyperkalemia associated with intravenous labetalol therapy for acute hypertension in renal transplant recipients. Clin Nephrol. 1990;33:269–71.PubMed Arthur S, Greenberg A. Hyperkalemia associated with intravenous labetalol therapy for acute hypertension in renal transplant recipients. Clin Nephrol. 1990;33:269–71.PubMed
21.
22.
go back to reference Rasmussen L, Husted SE, Johnsen SP. Severe intoxication after an intentional overdose of amlodipine. Acta Anaesthesiol Scand. 2003;47(8):1038–40.CrossRefPubMed Rasmussen L, Husted SE, Johnsen SP. Severe intoxication after an intentional overdose of amlodipine. Acta Anaesthesiol Scand. 2003;47(8):1038–40.CrossRefPubMed
23.
go back to reference Imamura T, Matsuura Y, Nagoshi T, Ishikawa T, Date H, Kita T, et al. Hyperkalemia induced by the calcium channel blocker, benidipine. Intern Med. 2003;42(6):503–6.CrossRefPubMed Imamura T, Matsuura Y, Nagoshi T, Ishikawa T, Date H, Kita T, et al. Hyperkalemia induced by the calcium channel blocker, benidipine. Intern Med. 2003;42(6):503–6.CrossRefPubMed
24.
go back to reference Freed MI, Rastegar A, Bia MJ. Effects of calcium channel blockers on potassium homeostasis. Yale J Biol Med. 1991;64(2):177–86.PubMedCentralPubMed Freed MI, Rastegar A, Bia MJ. Effects of calcium channel blockers on potassium homeostasis. Yale J Biol Med. 1991;64(2):177–86.PubMedCentralPubMed
25.
go back to reference Martyn JA, Richtsfeld M. Succinylcholine-induced hyperkalemia in acquired pathologic states: etiologic factors and molecular mechanisms. Anesthesiology. 2006;104(1):158–69.CrossRefPubMed Martyn JA, Richtsfeld M. Succinylcholine-induced hyperkalemia in acquired pathologic states: etiologic factors and molecular mechanisms. Anesthesiology. 2006;104(1):158–69.CrossRefPubMed
26.
go back to reference Gronert GA. Succinylcholine-induced hyperkalemia and beyond. 1975. Anesthesiology. 2009;111(6):1372–7.CrossRefPubMed Gronert GA. Succinylcholine-induced hyperkalemia and beyond. 1975. Anesthesiology. 2009;111(6):1372–7.CrossRefPubMed
27.
go back to reference Buckley MS, Leblanc JM, Cawley MJ. Electrolyte disturbances associated with commonly prescribed medications in the intensive care unit. Crit Care Med. 2010;38(6 Suppl):S253–64.CrossRefPubMed Buckley MS, Leblanc JM, Cawley MJ. Electrolyte disturbances associated with commonly prescribed medications in the intensive care unit. Crit Care Med. 2010;38(6 Suppl):S253–64.CrossRefPubMed
28.
go back to reference Fenton F, Smally AJ, Laut J. Hyperkalemia and digoxin toxicity in a patient with kidney failure. Ann Emerg Med. 1996;28(4):440–1.CrossRefPubMed Fenton F, Smally AJ, Laut J. Hyperkalemia and digoxin toxicity in a patient with kidney failure. Ann Emerg Med. 1996;28(4):440–1.CrossRefPubMed
29.
go back to reference Manini AF, Nelson LS, Hoffman RS. Prognostic utility of serum potassium in chronic digoxin toxicity: a case-control study. Am J Cardiovasc Drugs. 2011;11(3):173–8.CrossRefPubMed Manini AF, Nelson LS, Hoffman RS. Prognostic utility of serum potassium in chronic digoxin toxicity: a case-control study. Am J Cardiovasc Drugs. 2011;11(3):173–8.CrossRefPubMed
30.
go back to reference Papadakis MA, Wexman MP, Fraser C, Sedlacek SM. Hyperkalemia complicating digoxin toxicity in a patient with renal failure. Am J Kidney Dis. 1985;5(1):64–6.CrossRefPubMed Papadakis MA, Wexman MP, Fraser C, Sedlacek SM. Hyperkalemia complicating digoxin toxicity in a patient with renal failure. Am J Kidney Dis. 1985;5(1):64–6.CrossRefPubMed
31.
go back to reference Moreno M, Murphy C, Goldsmith C. Increase in serum potassium resulting from the administration of hypertonic mannitol and other solutions. J Lab Clin Med. 1969;73(2):291–8.PubMed Moreno M, Murphy C, Goldsmith C. Increase in serum potassium resulting from the administration of hypertonic mannitol and other solutions. J Lab Clin Med. 1969;73(2):291–8.PubMed
32.
go back to reference Manninen PH, Lam AM, Gelb AW, Brown SC. The effect of high-dose mannitol on serum and urine electrolytes and osmolality in neurosurgical patients. Can J Anaesth. 1987;34(5):442–6.CrossRefPubMed Manninen PH, Lam AM, Gelb AW, Brown SC. The effect of high-dose mannitol on serum and urine electrolytes and osmolality in neurosurgical patients. Can J Anaesth. 1987;34(5):442–6.CrossRefPubMed
33.
34.
go back to reference Tobita K, Kohno T. Case of hyperkalemia after the administration of hypertonic mannitol during craniotomy. Masui. 2010;59(5):641–4.PubMed Tobita K, Kohno T. Case of hyperkalemia after the administration of hypertonic mannitol during craniotomy. Masui. 2010;59(5):641–4.PubMed
35.
go back to reference Meneton P, Loffing J, Warnock DG. Sodium and potassium handling by the aldosterone-sensitive distal nephron: the pivotal role of the distal and connecting tubule. Am J Physiol Renal Physiol. 2004;287(4):F593–601.CrossRefPubMed Meneton P, Loffing J, Warnock DG. Sodium and potassium handling by the aldosterone-sensitive distal nephron: the pivotal role of the distal and connecting tubule. Am J Physiol Renal Physiol. 2004;287(4):F593–601.CrossRefPubMed
36.
go back to reference Staruschenko A. Regulation of transport in the connecting tubule and cortical collecting duct. Compr Physiol. 2012;2:1541–84.PubMedCentralPubMed Staruschenko A. Regulation of transport in the connecting tubule and cortical collecting duct. Compr Physiol. 2012;2:1541–84.PubMedCentralPubMed
37.
go back to reference Roscioni SS, de Zeeuw D, Bakker SJ, Lambers Heerspink HJ. Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy. Nat Rev Nephrol. 2012;8(12):691–9.CrossRefPubMed Roscioni SS, de Zeeuw D, Bakker SJ, Lambers Heerspink HJ. Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy. Nat Rev Nephrol. 2012;8(12):691–9.CrossRefPubMed
38.
go back to reference Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med. 2004;351(6):585–92.CrossRefPubMed Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med. 2004;351(6):585–92.CrossRefPubMed
39.
go back to reference Reardon LC, Macpherson DS. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry? Arch Intern Med. 1998;158(1):26–32.CrossRefPubMed Reardon LC, Macpherson DS. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry? Arch Intern Med. 1998;158(1):26–32.CrossRefPubMed
40.
go back to reference Weir MR, Rolfe M. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. Clin J Am Soc Nephrol. 2010;5(3):531–48.CrossRefPubMed Weir MR, Rolfe M. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. Clin J Am Soc Nephrol. 2010;5(3):531–48.CrossRefPubMed
41.
go back to reference Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol. 1995;75(12):793–5.CrossRefPubMed Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol. 1995;75(12):793–5.CrossRefPubMed
42.
go back to reference Raebel MA. Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Cardiovasc Ther. 2012;30(3):e156–66.CrossRefPubMed Raebel MA. Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Cardiovasc Ther. 2012;30(3):e156–66.CrossRefPubMed
43.
go back to reference Cheng H, Harris RC. Potential side effects of renin inhibitors—mechanisms based on comparison with other renin-angiotensin blockers. Expert Opin Drug Saf. 2006;5(5):631–41.CrossRefPubMed Cheng H, Harris RC. Potential side effects of renin inhibitors—mechanisms based on comparison with other renin-angiotensin blockers. Expert Opin Drug Saf. 2006;5(5):631–41.CrossRefPubMed
44.
go back to reference Park I, Sheen SS, Lim HS, Yoon D, Park MY, Lee SH, et al. Comparison of hyperkalemic risk in hospitalized patients treated with different angiotensin receptor blockers: a retrospective cohort study using a Korean clinical research database. Am J Cardiovasc Drugs. 2012;12(4):255–62.CrossRefPubMed Park I, Sheen SS, Lim HS, Yoon D, Park MY, Lee SH, et al. Comparison of hyperkalemic risk in hospitalized patients treated with different angiotensin receptor blockers: a retrospective cohort study using a Korean clinical research database. Am J Cardiovasc Drugs. 2012;12(4):255–62.CrossRefPubMed
45.
go back to reference Desai AS, Swedberg K, McMurray JJ, Granger CB, Yusuf S, Young JB, et al. Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program. J Am Coll Cardiol. 2007;50(20):1959–66.CrossRefPubMed Desai AS, Swedberg K, McMurray JJ, Granger CB, Yusuf S, Young JB, et al. Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program. J Am Coll Cardiol. 2007;50(20):1959–66.CrossRefPubMed
46.
go back to reference Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet. 2009;374(9704):1840–8.CrossRefPubMed Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet. 2009;374(9704):1840–8.CrossRefPubMed
47.
go back to reference Appel GB, Radhakrishnan J, Avram MM, DeFronzo RA, Escobar-Jimenez F, Campos MM, et al. Analysis of metabolic parameters as predictors of risk in the RENAAL study. Diabetes Care. 2003;26(5):1402–7.CrossRefPubMed Appel GB, Radhakrishnan J, Avram MM, DeFronzo RA, Escobar-Jimenez F, Campos MM, et al. Analysis of metabolic parameters as predictors of risk in the RENAAL study. Diabetes Care. 2003;26(5):1402–7.CrossRefPubMed
48.
go back to reference Miao Y, Dobre D, Heerspink HJ, Brenner BM, Cooper ME, Parving HH, et al. Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. Diabetologia. 2011;54(1):44–50.PubMedCentralCrossRefPubMed Miao Y, Dobre D, Heerspink HJ, Brenner BM, Cooper ME, Parving HH, et al. Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. Diabetologia. 2011;54(1):44–50.PubMedCentralCrossRefPubMed
49.
go back to reference Harel Z, Gilbert C, Wald R, Bell C, Perl J, Juurlink D, et al. The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis. BMJ. 2012;344:e42.PubMedCentralCrossRefPubMed Harel Z, Gilbert C, Wald R, Bell C, Perl J, Juurlink D, et al. The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis. BMJ. 2012;344:e42.PubMedCentralCrossRefPubMed
50.
go back to reference Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367(23):2204–13.CrossRefPubMed Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367(23):2204–13.CrossRefPubMed
51.
go back to reference Weir MR, Bush C, Anderson DR, Zhang J, Keefe D, Satlin A. Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis. J Am Soc Hypertens. 2007;1(4):264–77.CrossRefPubMed Weir MR, Bush C, Anderson DR, Zhang J, Keefe D, Satlin A. Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis. J Am Soc Hypertens. 2007;1(4):264–77.CrossRefPubMed
52.
go back to reference White WB, Bresalier R, Kaplan AP, Palmer BF, Riddell RH, Lesogor A, et al. Safety and tolerability of the direct renin inhibitor aliskiren: a pooled analysis of clinical experience in more than 12,000 patients with hypertension. J Clin Hypertens (Greenwich). 2010;12(10):765–75.CrossRef White WB, Bresalier R, Kaplan AP, Palmer BF, Riddell RH, Lesogor A, et al. Safety and tolerability of the direct renin inhibitor aliskiren: a pooled analysis of clinical experience in more than 12,000 patients with hypertension. J Clin Hypertens (Greenwich). 2010;12(10):765–75.CrossRef
53.
go back to reference Harirforoosh S, Jamali F. Renal adverse effects of nonsteroidal anti-inflammatory drugs. Expert Opin Drug Saf. 2009;8(6):669–81.CrossRefPubMed Harirforoosh S, Jamali F. Renal adverse effects of nonsteroidal anti-inflammatory drugs. Expert Opin Drug Saf. 2009;8(6):669–81.CrossRefPubMed
54.
go back to reference Bennett WM, Henrich WL, Stoff JS. The renal effects of nonsteroidal anti-inflammatory drugs: summary and recommendations. Am J Kidney Dis. 1996;28(1 Suppl 1):S56–62.CrossRefPubMed Bennett WM, Henrich WL, Stoff JS. The renal effects of nonsteroidal anti-inflammatory drugs: summary and recommendations. Am J Kidney Dis. 1996;28(1 Suppl 1):S56–62.CrossRefPubMed
55.
go back to reference Brater DC. Effects of nonsteroidal anti-inflammatory drugs on renal function: focus on cyclooxygenase-2-selective inhibition. Am J Med. 1999;107(6A):65S–70S discussion S-1S.CrossRefPubMed Brater DC. Effects of nonsteroidal anti-inflammatory drugs on renal function: focus on cyclooxygenase-2-selective inhibition. Am J Med. 1999;107(6A):65S–70S discussion S-1S.CrossRefPubMed
56.
go back to reference Preston RA, Hirsh MM, Oster MD Jr, Oster HM. University of Miami Division of Clinical Pharmacology therapeutic rounds: drug-induced hyperkalemia. Am J Ther. 1998;5(2):125–32.CrossRefPubMed Preston RA, Hirsh MM, Oster MD Jr, Oster HM. University of Miami Division of Clinical Pharmacology therapeutic rounds: drug-induced hyperkalemia. Am J Ther. 1998;5(2):125–32.CrossRefPubMed
57.
go back to reference Khanna A, White WB. The management of hyperkalemia in patients with cardiovascular disease. Am J Med. 2009;122(3):215–21.CrossRefPubMed Khanna A, White WB. The management of hyperkalemia in patients with cardiovascular disease. Am J Med. 2009;122(3):215–21.CrossRefPubMed
58.
go back to reference Zimran A, Kramer M, Plaskin M, Hershko C. Incidence of hyperkalaemia induced by indomethacin in a hospital population. Br Med J (Clin Res Ed). 1985;291(6488):107–8.CrossRef Zimran A, Kramer M, Plaskin M, Hershko C. Incidence of hyperkalaemia induced by indomethacin in a hospital population. Br Med J (Clin Res Ed). 1985;291(6488):107–8.CrossRef
59.
go back to reference Lafrance JP, Miller DR. Dispensed selective and nonselective nonsteroidal anti-inflammatory drugs and the risk of moderate to severe hyperkalemia: a nested case-control study. Am J Kidney Dis. 2012;60(1):82–9.CrossRefPubMed Lafrance JP, Miller DR. Dispensed selective and nonselective nonsteroidal anti-inflammatory drugs and the risk of moderate to severe hyperkalemia: a nested case-control study. Am J Kidney Dis. 2012;60(1):82–9.CrossRefPubMed
60.
go back to reference Aljadhey H, Tu W, Hansen RA, Blalock S, Brater DC, Murray MD. Risk of hyperkalemia associated with selective COX-2 inhibitors. Pharmacoepidemiol Drug Saf. 2010;19(11):1194–8.PubMedCentralCrossRefPubMed Aljadhey H, Tu W, Hansen RA, Blalock S, Brater DC, Murray MD. Risk of hyperkalemia associated with selective COX-2 inhibitors. Pharmacoepidemiol Drug Saf. 2010;19(11):1194–8.PubMedCentralCrossRefPubMed
61.
go back to reference Siebels M, Andrassy K, Vecsei P, Seelig HP, Back T, Nawroth P, et al. Dose dependent suppression of mineralocorticoid metabolism by different heparin fractions. Thromb Res. 1992;66(5):467–73.CrossRefPubMed Siebels M, Andrassy K, Vecsei P, Seelig HP, Back T, Nawroth P, et al. Dose dependent suppression of mineralocorticoid metabolism by different heparin fractions. Thromb Res. 1992;66(5):467–73.CrossRefPubMed
62.
go back to reference Oster JR, Singer I, Fishman LM. Heparin-induced aldosterone suppression and hyperkalemia. Am J Med. 1995;98(6):575–86.CrossRefPubMed Oster JR, Singer I, Fishman LM. Heparin-induced aldosterone suppression and hyperkalemia. Am J Med. 1995;98(6):575–86.CrossRefPubMed
63.
go back to reference Bhaskar B, Fraser JF, Mullaney D. Lest we forget: heparin-induced hyperkalemia. J Cardiothorac Vasc Anesth. 2012;26(1):106–9.CrossRefPubMed Bhaskar B, Fraser JF, Mullaney D. Lest we forget: heparin-induced hyperkalemia. J Cardiothorac Vasc Anesth. 2012;26(1):106–9.CrossRefPubMed
64.
go back to reference Gheno G, Cinetto L, Savarino C, Vellar S, Carraro M, Randon M. Variations of serum potassium level and risk of hyperkalemia in inpatients receiving low-molecular-weight heparin. Eur J Clin Pharmacol. 2003;59(5–6):373–7.CrossRefPubMed Gheno G, Cinetto L, Savarino C, Vellar S, Carraro M, Randon M. Variations of serum potassium level and risk of hyperkalemia in inpatients receiving low-molecular-weight heparin. Eur J Clin Pharmacol. 2003;59(5–6):373–7.CrossRefPubMed
65.
go back to reference Aull L, Chao H, Coy K. Heparin-induced hyperkalemia. DICP. 1990;24(3):244–6.PubMed Aull L, Chao H, Coy K. Heparin-induced hyperkalemia. DICP. 1990;24(3):244–6.PubMed
66.
go back to reference Koren-Michowitz M, Avni B, Michowitz Y, Moravski G, Efrati S, Golik A. Early onset of hyperkalemia in patients treated with low molecular weight heparin: a prospective study. Pharmacoepidemiol Drug Saf. 2004;13(5):299–302.CrossRefPubMed Koren-Michowitz M, Avni B, Michowitz Y, Moravski G, Efrati S, Golik A. Early onset of hyperkalemia in patients treated with low molecular weight heparin: a prospective study. Pharmacoepidemiol Drug Saf. 2004;13(5):299–302.CrossRefPubMed
67.
go back to reference Danguy C, Biston P, Carlier E, Defrance P, Piagnerelli M. Severe hyperkalemia in critically ill patients treated with prophylactic doses of enoxaparin. Intensive Care Med. 2012;38(11):1904–5.CrossRefPubMed Danguy C, Biston P, Carlier E, Defrance P, Piagnerelli M. Severe hyperkalemia in critically ill patients treated with prophylactic doses of enoxaparin. Intensive Care Med. 2012;38(11):1904–5.CrossRefPubMed
68.
go back to reference Marcelli JM, Lalau JD, Abourachid H, Quiret JC, Quichaud J. Unlike heparin, low-molecular weight heparin does not suppress aldosterone production. Horm Metab Res. 1989;21(7):402.CrossRefPubMed Marcelli JM, Lalau JD, Abourachid H, Quiret JC, Quichaud J. Unlike heparin, low-molecular weight heparin does not suppress aldosterone production. Horm Metab Res. 1989;21(7):402.CrossRefPubMed
69.
go back to reference Rangel EB. The metabolic and toxicological considerations for immunosuppressive drugs used during pancreas transplantation. Expert Opin Drug Metab Toxicol. 2012;8(12):1531–48.CrossRefPubMed Rangel EB. The metabolic and toxicological considerations for immunosuppressive drugs used during pancreas transplantation. Expert Opin Drug Metab Toxicol. 2012;8(12):1531–48.CrossRefPubMed
70.
go back to reference Caliskan Y, Kalayoglu-Besisik S, Sargin D, Ecder T. Cyclosporine-associated hyperkalemia: report of four allogeneic blood stem-cell transplant cases. Transplantation. 2003;75(7):1069–72.CrossRefPubMed Caliskan Y, Kalayoglu-Besisik S, Sargin D, Ecder T. Cyclosporine-associated hyperkalemia: report of four allogeneic blood stem-cell transplant cases. Transplantation. 2003;75(7):1069–72.CrossRefPubMed
71.
go back to reference Laine J, Holmberg C. Renal and adrenal mechanisms in cyclosporine-induced hyperkalaemia after renal transplantation. Eur J Clin Invest. 1995;25(9):670–6.CrossRefPubMed Laine J, Holmberg C. Renal and adrenal mechanisms in cyclosporine-induced hyperkalaemia after renal transplantation. Eur J Clin Invest. 1995;25(9):670–6.CrossRefPubMed
72.
go back to reference Heering P, Grabensee B. Influence of ciclosporin A on renal tubular function after kidney transplantation. Nephron. 1991;59(1):66–70.CrossRefPubMed Heering P, Grabensee B. Influence of ciclosporin A on renal tubular function after kidney transplantation. Nephron. 1991;59(1):66–70.CrossRefPubMed
73.
go back to reference Funder JW. Eplerenone: hypertension, heart failure and the importance of mineralocorticoid receptor blockade. Future Cardiol. 2006;2(5):535–41.CrossRefPubMed Funder JW. Eplerenone: hypertension, heart failure and the importance of mineralocorticoid receptor blockade. Future Cardiol. 2006;2(5):535–41.CrossRefPubMed
74.
75.
go back to reference Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709–17.CrossRefPubMed Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709–17.CrossRefPubMed
76.
go back to reference Pitt B, Bakris G, Ruilope LM, DiCarlo L, Mukherjee R, Investigators E. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation. 2008;118(16):1643–50.CrossRefPubMed Pitt B, Bakris G, Ruilope LM, DiCarlo L, Mukherjee R, Investigators E. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation. 2008;118(16):1643–50.CrossRefPubMed
77.
go back to reference Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351(6):543–51.CrossRefPubMed Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351(6):543–51.CrossRefPubMed
78.
go back to reference Dinsdale C, Wani M, Steward J, O’Mahony MS. Tolerability of spironolactone as adjunctive treatment for heart failure in patients over 75 years of age. Age Ageing. 2005;34(4):395–8.CrossRefPubMed Dinsdale C, Wani M, Steward J, O’Mahony MS. Tolerability of spironolactone as adjunctive treatment for heart failure in patients over 75 years of age. Age Ageing. 2005;34(4):395–8.CrossRefPubMed
79.
go back to reference Wei L, Struthers AD, Fahey T, Watson AD, Macdonald TM. Spironolactone use and renal toxicity: population based longitudinal analysis. BMJ. 2010;340:c1768.CrossRefPubMed Wei L, Struthers AD, Fahey T, Watson AD, Macdonald TM. Spironolactone use and renal toxicity: population based longitudinal analysis. BMJ. 2010;340:c1768.CrossRefPubMed
80.
go back to reference Greenblatt DJ, Koch-Weser J. Adverse reactions to spironolactone. A report from the boston collaborative drug surveillance program. JAMA. 1973;225(1):40–3.CrossRefPubMed Greenblatt DJ, Koch-Weser J. Adverse reactions to spironolactone. A report from the boston collaborative drug surveillance program. JAMA. 1973;225(1):40–3.CrossRefPubMed
81.
go back to reference Svensson M, Gustafsson F, Galatius S, Hildebrandt PR, Atar D. How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? J Card Fail. 2004;10(4):297–303.CrossRefPubMed Svensson M, Gustafsson F, Galatius S, Hildebrandt PR, Atar D. How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? J Card Fail. 2004;10(4):297–303.CrossRefPubMed
82.
go back to reference Epstein M, Calhoun DA. Aldosterone blockers (mineralocorticoid receptor antagonism) and potassium-sparing diuretics. J Clin Hypertens (Greenwich). 2011;13(9):644–8.CrossRef Epstein M, Calhoun DA. Aldosterone blockers (mineralocorticoid receptor antagonism) and potassium-sparing diuretics. J Clin Hypertens (Greenwich). 2011;13(9):644–8.CrossRef
84.
go back to reference Chiu TF, Bullard MJ, Chen JC, Liaw SJ, Ng CJ. Rapid life-threatening hyperkalemia after addition of amiloride HCl/hydrochlorothiazide to angiotensin-converting enzyme inhibitor therapy. Ann Emerg Med. 1997;30(5):612–5.CrossRefPubMed Chiu TF, Bullard MJ, Chen JC, Liaw SJ, Ng CJ. Rapid life-threatening hyperkalemia after addition of amiloride HCl/hydrochlorothiazide to angiotensin-converting enzyme inhibitor therapy. Ann Emerg Med. 1997;30(5):612–5.CrossRefPubMed
85.
go back to reference Quan KC, Kahana L. Clinical experience with the diuretic effects of triamterene alone and combined with hydrochlorothiazide. Curr Ther Res Clin Exp. 1964;6:27–34.PubMed Quan KC, Kahana L. Clinical experience with the diuretic effects of triamterene alone and combined with hydrochlorothiazide. Curr Ther Res Clin Exp. 1964;6:27–34.PubMed
88.
go back to reference Choi MJ, Fernandez PC, Patnaik A, Coupaye-Gerard B, D’Andrea D, Szerlip H, et al. Brief report: trimethoprim-induced hyperkalemia in a patient with AIDS. N Engl J Med. 1993;328(10):703–6.CrossRefPubMed Choi MJ, Fernandez PC, Patnaik A, Coupaye-Gerard B, D’Andrea D, Szerlip H, et al. Brief report: trimethoprim-induced hyperkalemia in a patient with AIDS. N Engl J Med. 1993;328(10):703–6.CrossRefPubMed
89.
go back to reference Zietse R, Zoutendijk R, Hoorn EJ. Fluid, electrolyte and acid-base disorders associated with antibiotic therapy. Nat Rev Nephrol. 2009;5(4):193–202.CrossRefPubMed Zietse R, Zoutendijk R, Hoorn EJ. Fluid, electrolyte and acid-base disorders associated with antibiotic therapy. Nat Rev Nephrol. 2009;5(4):193–202.CrossRefPubMed
90.
91.
go back to reference Perazella MA. Trimethoprim-induced hyperkalaemia: clinical data, mechanism, prevention and management. Drug Saf. 2000;22(3):227–36.CrossRefPubMed Perazella MA. Trimethoprim-induced hyperkalaemia: clinical data, mechanism, prevention and management. Drug Saf. 2000;22(3):227–36.CrossRefPubMed
92.
go back to reference Ackerman BH, Patton ML, Guilday RE, Haith LR Jr, Stair-Buchmann M, Reigart CL. Trimethoprim-induced hyperkalemia in burn patients treated with intravenous or oral trimethoprim sulfamethoxazole for methicillin-resistant Staphylococcus aureus and other infections: nature or nurture? J Burn Care Res. 2013;34(1):127–32.CrossRefPubMed Ackerman BH, Patton ML, Guilday RE, Haith LR Jr, Stair-Buchmann M, Reigart CL. Trimethoprim-induced hyperkalemia in burn patients treated with intravenous or oral trimethoprim sulfamethoxazole for methicillin-resistant Staphylococcus aureus and other infections: nature or nurture? J Burn Care Res. 2013;34(1):127–32.CrossRefPubMed
93.
go back to reference Antoniou T, Gomes T, Juurlink DN, Loutfy MR, Glazier RH, Mamdani MM. Trimethoprim-sulfamethoxazole-induced hyperkalemia in patients receiving inhibitors of the renin-angiotensin system: a population-based study. Arch Intern Med. 2010;170(12):1045–9.CrossRefPubMed Antoniou T, Gomes T, Juurlink DN, Loutfy MR, Glazier RH, Mamdani MM. Trimethoprim-sulfamethoxazole-induced hyperkalemia in patients receiving inhibitors of the renin-angiotensin system: a population-based study. Arch Intern Med. 2010;170(12):1045–9.CrossRefPubMed
94.
go back to reference Kleyman TR, Roberts C, Ling BN. A mechanism for pentamidine-induced hyperkalemia: inhibition of distal nephron sodium transport. Ann Intern Med. 1995;122(2):103–6.CrossRefPubMed Kleyman TR, Roberts C, Ling BN. A mechanism for pentamidine-induced hyperkalemia: inhibition of distal nephron sodium transport. Ann Intern Med. 1995;122(2):103–6.CrossRefPubMed
95.
go back to reference Gabriels G, Stockem E, Greven J. Potassium-sparing renal effects of trimethoprim and structural analogues. Nephron. 2000;86(1):70–8.CrossRefPubMed Gabriels G, Stockem E, Greven J. Potassium-sparing renal effects of trimethoprim and structural analogues. Nephron. 2000;86(1):70–8.CrossRefPubMed
96.
go back to reference Buff DD, Aboal AA. Pentamidine-associated renal dysfunction and hyperkalemia. Am J Med. 1990;88(5):552.CrossRefPubMed Buff DD, Aboal AA. Pentamidine-associated renal dysfunction and hyperkalemia. Am J Med. 1990;88(5):552.CrossRefPubMed
97.
go back to reference O’Brien JG, Dong BJ, Coleman RL, Gee L, Balano KB. A 5-year retrospective review of adverse drug reactions and their risk factors in human immunodeficiency virus-infected patients who were receiving intravenous pentamidine therapy for Pneumocystis carinii pneumonia. Clin Infect Dis. 1997;24(5):854–9.CrossRefPubMed O’Brien JG, Dong BJ, Coleman RL, Gee L, Balano KB. A 5-year retrospective review of adverse drug reactions and their risk factors in human immunodeficiency virus-infected patients who were receiving intravenous pentamidine therapy for Pneumocystis carinii pneumonia. Clin Infect Dis. 1997;24(5):854–9.CrossRefPubMed
98.
go back to reference Briceland LL, Bailie GR. Pentamidine-associated nephrotoxicity and hyperkalemia in patients with AIDS. DICP. 1991;25(11):1171–4.PubMed Briceland LL, Bailie GR. Pentamidine-associated nephrotoxicity and hyperkalemia in patients with AIDS. DICP. 1991;25(11):1171–4.PubMed
99.
go back to reference Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC. Hyperkalemia from single small oral doses of potassium chloride. Nephron. 1984;36(4):270–1.CrossRefPubMed Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC. Hyperkalemia from single small oral doses of potassium chloride. Nephron. 1984;36(4):270–1.CrossRefPubMed
100.
go back to reference Lawson DH. Adverse reactions to potassium chloride. Q J Med. 1974;43(171):433–40.PubMed Lawson DH. Adverse reactions to potassium chloride. Q J Med. 1974;43(171):433–40.PubMed
101.
go back to reference John SK, Rangan Y, Block CA, Koff MD. Life-threatening hyperkalemia from nutritional supplements: uncommon or undiagnosed? Am J Emerg Med. 2011;29(9):1237e1–2.CrossRef John SK, Rangan Y, Block CA, Koff MD. Life-threatening hyperkalemia from nutritional supplements: uncommon or undiagnosed? Am J Emerg Med. 2011;29(9):1237e1–2.CrossRef
103.
go back to reference Ray K, Dorman S, Watson R. Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction. J Hum Hypertens. 1999;13(10):717–20.CrossRefPubMed Ray K, Dorman S, Watson R. Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction. J Hum Hypertens. 1999;13(10):717–20.CrossRefPubMed
104.
go back to reference Dent A, Walmsley D, Dhandapani S. Hyperkalaemia is a risk with low sodium salt in vulnerable patients. BMJ. 2011;343:d4514.CrossRefPubMed Dent A, Walmsley D, Dhandapani S. Hyperkalaemia is a risk with low sodium salt in vulnerable patients. BMJ. 2011;343:d4514.CrossRefPubMed
105.
go back to reference Lyons KS, McGlinchey P. Hyperkalaemic cardiac arrhythmia due to prolonged ingestion of potassium citrate. Int J Cardiol. 2009;131(3):e134–6.CrossRefPubMed Lyons KS, McGlinchey P. Hyperkalaemic cardiac arrhythmia due to prolonged ingestion of potassium citrate. Int J Cardiol. 2009;131(3):e134–6.CrossRefPubMed
106.
107.
go back to reference Chen J, Singhapricha T, Memarzadeh M, Ziman A, Yuan S, Hu KQ, et al. Storage age of transfused red blood cells during liver transplantation and its intraoperative and postoperative effects. World J Surg. 2012;36(10):2436–42.CrossRefPubMed Chen J, Singhapricha T, Memarzadeh M, Ziman A, Yuan S, Hu KQ, et al. Storage age of transfused red blood cells during liver transplantation and its intraoperative and postoperative effects. World J Surg. 2012;36(10):2436–42.CrossRefPubMed
108.
go back to reference Zimrin AB, Hess JR. Current issues relating to the transfusion of stored red blood cells. Vox Sang. 2009;96(2):93–103.CrossRefPubMed Zimrin AB, Hess JR. Current issues relating to the transfusion of stored red blood cells. Vox Sang. 2009;96(2):93–103.CrossRefPubMed
109.
go back to reference Barcia JP. Hyperkalemia associated with rapid infusion of conventional and lipid complex formulations of amphotericin B. Pharmacotherapy. 1998;18(4):874–6.PubMed Barcia JP. Hyperkalemia associated with rapid infusion of conventional and lipid complex formulations of amphotericin B. Pharmacotherapy. 1998;18(4):874–6.PubMed
110.
go back to reference Zaleski M, Dabage N, Paixao R, Muniz J. Dabigatran-induced hyperkalemia in a renal transplant recipient: a clinical observation. J Clin Pharmacol. 2013;53(4):456–8.CrossRefPubMed Zaleski M, Dabage N, Paixao R, Muniz J. Dabigatran-induced hyperkalemia in a renal transplant recipient: a clinical observation. J Clin Pharmacol. 2013;53(4):456–8.CrossRefPubMed
111.
go back to reference Marusic S, Gojo-Tomic N, Bacic-Vrca V, Bozikov V. Hyperkalaemia associated with hydroxyurea in a patient with polycythaemia vera. Eur J Clin Pharmacol. 2011;67(7):757–8.CrossRefPubMed Marusic S, Gojo-Tomic N, Bacic-Vrca V, Bozikov V. Hyperkalaemia associated with hydroxyurea in a patient with polycythaemia vera. Eur J Clin Pharmacol. 2011;67(7):757–8.CrossRefPubMed
112.
go back to reference Iglesias MH, Giesbrecht EM, von Dadelszen P, Magee LA. Postpartum hyperkalemia associated with magnesium sulfate. Hypertens Pregnancy. 2011;30(4):481–4.CrossRefPubMed Iglesias MH, Giesbrecht EM, von Dadelszen P, Magee LA. Postpartum hyperkalemia associated with magnesium sulfate. Hypertens Pregnancy. 2011;30(4):481–4.CrossRefPubMed
113.
go back to reference Kitagawa H, Chang H, Fujita T. Hyperkalemia due to nafamostat mesylate. N Engl J Med. 1995;332(10):687.CrossRefPubMed Kitagawa H, Chang H, Fujita T. Hyperkalemia due to nafamostat mesylate. N Engl J Med. 1995;332(10):687.CrossRefPubMed
114.
115.
go back to reference Lee HH, Hsu PC, Lin TH, Lai WT, Sheu SH. Nicorandil-induced hyperkalemia in a uremic patient. Case Rep Med. 2012;2012:812178.PubMedCentralPubMed Lee HH, Hsu PC, Lin TH, Lai WT, Sheu SH. Nicorandil-induced hyperkalemia in a uremic patient. Case Rep Med. 2012;2012:812178.PubMedCentralPubMed
116.
go back to reference Adabala M, Jhaveri KD, Gitman M. Severe hyperkalaemia resulting from octreotide use in a haemodialysis patient. Nephrol Dial Transplant. 2010;25(10):3439–42.CrossRefPubMed Adabala M, Jhaveri KD, Gitman M. Severe hyperkalaemia resulting from octreotide use in a haemodialysis patient. Nephrol Dial Transplant. 2010;25(10):3439–42.CrossRefPubMed
117.
go back to reference Tashiro M, Yoshikawa I, Kume K, Narita R, Sugihara Y, Otsuki M. Acute hyperkalemia associated with intravenous omeprazole therapy. Am J Gastroenterol. 2003;98(5):1209–10.CrossRefPubMed Tashiro M, Yoshikawa I, Kume K, Narita R, Sugihara Y, Otsuki M. Acute hyperkalemia associated with intravenous omeprazole therapy. Am J Gastroenterol. 2003;98(5):1209–10.CrossRefPubMed
118.
go back to reference Gau JT, Heh V, Acharya U, Yang YX, Kao TC. Uses of proton pump inhibitors and serum potassium levels. Pharmacoepidemiol Drug Saf. 2009;18(9):865–71.CrossRefPubMed Gau JT, Heh V, Acharya U, Yang YX, Kao TC. Uses of proton pump inhibitors and serum potassium levels. Pharmacoepidemiol Drug Saf. 2009;18(9):865–71.CrossRefPubMed
119.
120.
go back to reference Harris E, Behrens J, Samson D, Rahemtulla A, Russell NH, Byrne JL. Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia. Br J Haematol. 2003;122(1):160–1.CrossRefPubMed Harris E, Behrens J, Samson D, Rahemtulla A, Russell NH, Byrne JL. Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia. Br J Haematol. 2003;122(1):160–1.CrossRefPubMed
121.
go back to reference Panteliou E, Young N, Naysmith M. Life-threatening hyperkalemia following zoledronic acid infusion for Paget’s disease: a case report. J Med Case Rep. 2011;5:367.PubMedCentralCrossRefPubMed Panteliou E, Young N, Naysmith M. Life-threatening hyperkalemia following zoledronic acid infusion for Paget’s disease: a case report. J Med Case Rep. 2011;5:367.PubMedCentralCrossRefPubMed
122.
go back to reference Raebel MA, Ross C, Xu S, Roblin DW, Cheetham C, Blanchette CM, et al. Diabetes and drug-associated hyperkalemia: effect of potassium monitoring. J Gen Intern Med. 2010;25(4):326–33.PubMedCentralCrossRefPubMed Raebel MA, Ross C, Xu S, Roblin DW, Cheetham C, Blanchette CM, et al. Diabetes and drug-associated hyperkalemia: effect of potassium monitoring. J Gen Intern Med. 2010;25(4):326–33.PubMedCentralCrossRefPubMed
123.
go back to reference Bush TM, Shlotzhauer TL, Imai K. Nonsteroidal anti-inflammatory drugs. Proposed guidelines for monitoring toxicity. West J Med. 1991;155(1):39–42.PubMedCentralPubMed Bush TM, Shlotzhauer TL, Imai K. Nonsteroidal anti-inflammatory drugs. Proposed guidelines for monitoring toxicity. West J Med. 1991;155(1):39–42.PubMedCentralPubMed
124.
go back to reference Hoskote SS, Joshi SR, Ghosh AK. Disorders of potassium homeostasis: pathophysiology and management. J Assoc Physicians India. 2008;56:685–93.PubMed Hoskote SS, Joshi SR, Ghosh AK. Disorders of potassium homeostasis: pathophysiology and management. J Assoc Physicians India. 2008;56:685–93.PubMed
125.
go back to reference ECC Committee, Subcommittees and Task Forces of the American Heart Association. 2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2005;112(24 Suppl): IV1-203. ECC Committee, Subcommittees and Task Forces of the American Heart Association. 2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2005;112(24 Suppl): IV1-203.
126.
go back to reference Weiner ID, Wingo CS. Hyperkalemia: a potential silent killer. J Am Soc Nephrol. 1998;9(8):1535–43.PubMed Weiner ID, Wingo CS. Hyperkalemia: a potential silent killer. J Am Soc Nephrol. 1998;9(8):1535–43.PubMed
127.
go back to reference Chapagain A, Ashman N. Hyperkalaemia in the age of aldosterone antagonism. QJM. 2012;105(11):1049–57.CrossRefPubMed Chapagain A, Ashman N. Hyperkalaemia in the age of aldosterone antagonism. QJM. 2012;105(11):1049–57.CrossRefPubMed
128.
go back to reference Levine M, Nikkanen H, Pallin DJ. The effects of intravenous calcium in patients with digoxin toxicity. J Emerg Med. 2011;40(1):41–6.CrossRefPubMed Levine M, Nikkanen H, Pallin DJ. The effects of intravenous calcium in patients with digoxin toxicity. J Emerg Med. 2011;40(1):41–6.CrossRefPubMed
129.
go back to reference Dick TB, Raines AA, Stinson JB, Collingridge DS, Harmston GE. Fludrocortisone is effective in the management of tacrolimus-induced hyperkalemia in liver transplant recipients. Transplant Proc. 2011;43(7):2664–8.CrossRefPubMed Dick TB, Raines AA, Stinson JB, Collingridge DS, Harmston GE. Fludrocortisone is effective in the management of tacrolimus-induced hyperkalemia in liver transplant recipients. Transplant Proc. 2011;43(7):2664–8.CrossRefPubMed
Metadata
Title
Drug-Induced Hyperkalemia
Authors
Chaker Ben Salem
Atef Badreddine
Neila Fathallah
Raoudha Slim
Houssem Hmouda
Publication date
01-09-2014
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 9/2014
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.1007/s40264-014-0196-1

Other articles of this Issue 9/2014

Drug Safety 9/2014 Go to the issue